AT-2266 (1-ethyl-6fluoro-1,4-dihydro-4oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid) showed marked activity in vivo when administered orally to mice bearing systemic, pulmonary, dermal, or urinary tract infections due to variety of organisms. The activity of AT-2266 was uniformly higher than those of norfloxacin, pipemidic acid, and nalidixic acid against all of the infections. The activity of AT-2266 administered orally was almost comparable to that of gentamicin administered subcutaneously against urinary tract infections due to gram-negative organisms but was generally lower against other infections. AT-2266 exhibited significant activity against infections due to gentamicin-resistant and nalidixic acid-resistant organisms.
AT-2266 (1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1 ,8-naphthyridine-3-carboxylic acid) is a pyridonecarboxylic acid derivative with broad and potent antibacterial activity (16) . It is well absorbed by the oral route, distributed to tissues at concentrations higher than plasma levels, and excreted into urine in large quantities (12) . Preliminary in vivo studies have shown that AT-2266 administered orally is generally more effective than are related compounds against systemic and urinary tract infections in mice (16) . The present paper details results of comparative evaluations ofthe activities ofAT-2266, norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
MATEIUALS AND METHODS
Drug. AT-2266 (10) , norfloxacin (6) , pipemidic acid (9) , and nalidixic acid (15) were prepared in our laboratories as described previously. Although AT-2266 and pipemidic acid were prepared as sesquihydrate and trihydrte, respectively, doses or concentrations were expressed in terms of anhydrous compound. All compounds were dissolved in water with equimolar NaOH for determinations of minimal inhibitory concentrations (MICs) and suspended in 0.2% carboxymethyl cellulose for oral administration. Gentamicin sulfate (Shionogi Co., Ltd.) was dissolved in water for both in vitro and in vivo experiments.
Orgawn . The organisms utized for experimental infections were stock strains stored at -70°C in our laboratories and subcultured just before use.
Deter1ndatlo. of MICs. MICs were determined by the twofold agar dilution method as described previously (17) . The 12.5 "g/ml, were equal to or 2 to 4 times higher than those of norfloxacin, 1/4 to 1/32 those of pipemidic acid, 1/4 to less than 1/256 those of nalidixic acid, and 1/32 to 4 times higher than those of gentamicin.
Comparative activities againt systemic Infectin. The therapeutic activities of AT-2266 were compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin in systemic infection models in mice ( In dermal infections, the ED50 of AT-2266 (15.3 mg/kg) was about 1/2 that of norfloxacin (27.3 mg/kg), about 1/11 that of pipemidic acid (173 mg/kg), <1/13 that of nalidixic acid (>200 mg/kg) and about 11 times greater than that of gentamicin (1.4 mg/kg).
In urinary tract infections, the ED50s of AT-2266 (1.5 to 17.8 mg/kg) were about 1/2 to 1/7 those of norfloxacin (3.4 to 55.8 mg/kg), 1/2 to 1/12 those of pipemidic acid (3.4 to 161 mg/kg), and 1/4 to 1/160 those of nalidixic acid (6.6 to >400 mg/kg). The ED50s of gentamicin (0.50 to 7.3 mg/kg) were similar to those of AT-2266 (1.5 to 5.0 mg/kg), except for infections with Staphylococcus aureus, against which the ED50 of gentamicin (1.6 mg/kg) was about 1/11 that of AT-2266 (17.8 mg/kg).
Comparative atvites against systemic infections due to n c c resist orgs . Since AT-2266 was active against nalidixic acidresistant organisms in vitro (16) nonfermentative organisms (16) . Its in vitro antibacterial activity is generally much higher than those of pipemidic acid and nalidixic acid (16) and similar to that of norfloxacin (2), which has been reported to be more active than frequently used P-lactams and aminoglycosides against most gram-negative organisms (4, 5, 13) . AT-2266 is well absorbed orally, and its levels in urine, bile, and tissues are generally higher than those in plasma (12) . These antibacterial and pharmacological properties of AT-2266 suggest that the compound might be effective against infections with various organisms at a variety of sites. This possibility was examined in the present study, in which systemic, pulmonary, dermal, and urinary tract infections were induced in mice. AT-2266 was effective orally against all infections and was uniformly more active than was norfloxacin, which had been reported to be highly active, in vivo (1), even when the infecting organisms were more susceptible to norfloxacin in vitro. AT-2266 was generally more effective than pipemidic and nalidixic acids against all infections. Pipemidic acid is reportedly more effective than oral antibiotics such as ampicillin and cephalexin against experimental infections due to gram-negative organisms (18) and in clinical trials (3, 7, 14) . 
